Philips has formed a new cardio-oncology partnership with U.S. cardiac MRI software developer, Myocardial Solutions.
The collaboration aims to improve survival rates and bridge a significant gap between heart and cancer care, Philips said. A combination of the MRI acquisition sequence Fast-SENC, the MyoStrain analysis tool, and Philips' SmartSpeed and BlueSeal technologies will be used to identify heart disease due to cardiotoxicity in cancer survivors and patients undergoing cancer therapies.
Philips said the technologies can detect heart failure across 48 segments of the heart in 10 minutes, with less than five minutes of analysis time to help identify regional dysfunction before it impacts the entire heart.
German researcher Prof. Dr. Sebastian Kelle from the German Heart Center and Charité University Medicine in Berlin will present his experience using the technologies during the Society for Cardiovascular Magnetic Resonance Annual Scientific Congress in Washington, DC.
